ストックスクリーナーアプリを入手
11.54
2.30%
0.2448
前日終値:
$11.29
開ける：
$11.44
24時間の取引高:
3.10M
Relative Volume:
1.39
時価総額：
$1.36B
収益：
-
当期純損益:
$-294.51M
株価収益率:
-3.2415
EPS:
-3.56
ネットキャッシュフロー:
$-244.42M
1週間 パフォーマンス:
-2.57%
1か月 パフォーマンス:
+53.05%
6か月 パフォーマンス:
-59.43%
1年 パフォーマンス:
-55.47%
1日の値動き範囲:
$11.18
$12.01
1週間の範囲:
$9.17
$12.01
52週間の値動き範囲:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
DYN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
11.53 | 1.36B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.55 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.40 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
550.34 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.09 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.48 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-12-13 | 開始されました | Robert W. Baird | Outperform |
| 2024-11-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-10-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 繰り返されました | Chardan Capital Markets | Buy |
| 2024-04-30 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2023-02-27 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 開始されました | Oppenheimer | Outperform |
| 2023-01-26 | 開始されました | Guggenheim | Buy |
| 2022-07-20 | 開始されました | Chardan Capital Markets | Buy |
| 2022-07-12 | 開始されました | Raymond James | Outperform |
| 2020-10-12 | 開始されました | JP Morgan | Overweight |
| 2020-10-12 | 開始されました | Jefferies | Buy |
| 2020-10-12 | 開始されました | Piper Sandler | Overweight |
| 2020-10-12 | 開始されました | Stifel | Buy |
すべてを表示
Dyne Therapeutics Inc (DYN) 最新ニュース
Dyne Therapeutics (DYN) Price Target Lowered by HC Wainwright & Co. | DYN Stock News - GuruFocus
RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright Adjusts Price Target for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Chardan Capital Reconfirms Buy Rating for Dyne Therapeutics (DYN) | DYN Stock News - GuruFocus
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Dyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Eyes Accelerated Approval for Key Programs by 2026 | DYN Stock News - GuruFocus
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
Dyne Therapeutics, Inc. SEC 10-Q Report - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationDYN - ACCESS Newswire
Is Dyne Therapeutics Inc. (NASDAQ:DYN) the Most Promising Small-Cap Stock According to Analysts? - Insider Monkey
EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy - Yahoo Finance
11 Most Promising Small-Cap Stocks According to Analysts - Insider Monkey
Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment - marketscreener.com
Dyne Therapeutics stock rises on orphan drug status By Investing.com - Investing.com Canada
Dyne Therapeutics stock rises on orphan drug status - Investing.com
Dyne Therapeutics (DYN) Gains EU Orphan Drug Status for DYNE-251 - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orpha - GuruFocus
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation For DYNE-251 In Duchenne Muscular Dystrophy - marketscreener.com
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy - The Manila Times
Dyne Therapeutics Receives European Medicines Agency (EMA) - GlobeNewswire
Breakthrough DMD Treatment DYNE-251 Wins Crucial EU Orphan Status as Phase 1/2 Trial Shows Promise - Stock Titan
Dyne Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.06m - simplywall.st
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne - Endpoints News
More C-suite changes at Dyne - BioCentury
Dyne Therapeutics reshapes leadership team ahead of drug launches By Investing.com - Investing.com South Africa
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Enhances Leadership Team with Key Appoin - GuruFocus
Dyne Therapeutics Announces Chief Business Officer and Chief Sci - GuruFocus
Dyne Therapeutics reshapes leadership team ahead of drug launches - Investing.com
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - The Manila Times
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics Reveals Strategic Compensation Plan: 330K Stock Options Granted - Stock Titan
Dyne wins new Outperform at BMO on prospects for lead drug - MSN
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m - Yahoo
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Ex-Dyne team members reconvene at Crescent - biocentury.com
RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk - MarketScreener
FORCE platform boosts muscle function in dystrophic mice - BioWorld MedTech
Oversold Conditions For Dyne Therapeutics - Nasdaq
FORCE platform leads to Duchenne muscular dystrophy mouse model - BioWorld MedTech
Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals
BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada
Dyne Therapeutics Inc (DYN) 財務データ
収益
当期純利益
現金流量
EPS
Dyne Therapeutics Inc (DYN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Mar 11 '25 |
Sale |
11.38 |
1,343 |
15,283 |
122,330 |
| Beskrovnaya Oxana | Chief Scientific Officer |
Mar 11 '25 |
Sale |
11.38 |
2,153 |
24,501 |
195,840 |
2.11%
0.83%
大文字化:
|
ボリューム (24 時間):